Alberto Bianchinotti

Merlin Nexus is a company focused on crossover private equity investing in the life sciences industry. Merlin Nexus invests globally in private and public healthcare companies. With its first fund launched in 2001 by Dominique Semon, Merlin Nexus now has several crossover private equity funds and a public-only fund, with commitments totaling $200 million. The Merlin Nexus objective is to realize long-term capital appreciation from investments in: Late-stage private companies; PIPEs (Private Investments in Public Equity); and select, long-term, open market investments. Unlike venture capital funds, Merlin Nexus funds are distinguished by relatively high liquidity and by short, 5-year maturities. The firm targets for each private investment a potential for liquidity within 24 months after initial investment, as well as a 2-3 times return on invested capital.